The claim
“NMN activates your longevity genes and extends your lifespan.”
Formulations along these lines are common in longevity supplement marketing. For foods and food supplements in the EU, they are particularly problematic: they promise a broad health effect that has no regulatory basis and goes substantially beyond the available human evidence.
What the evidence actually shows
Animal studies: interesting, but not transferable
The widely cited Mills et al. (2016) study showed improvements in a range of age-related parameters in aged mice. Such results are scientifically relevant to the understanding of NAD+ metabolism and ageing biology. They do not transfer directly to human outcomes, and they certainly do not demonstrate lifespan extension in people.
Human studies: substantially weaker
Available human trials with NMN primarily show:
- Increases in certain NAD+ metabolites in blood — confirming that NMN is absorbed and converted to NAD+ in humans
- Some changes in metabolic markers in selected populations (e.g., postmenopausal women, older adults)
- No data on lifespan
Measuring a surrogate biomarker (NAD+ levels) is not equivalent to demonstrating a clinical outcome (longer life or healthier ageing). This gap between biomarker and outcome is large and has not been bridged.
The core problem with the claim
Lifespan extension is not measurable in short-term human trials. Deriving a lifespan claim directly from animal data skips multiple layers of scientific uncertainty: species differences in NAD+ metabolism, dose translation, human genetic variation, and the inability of any existing trial to actually measure human lifespan.
EFSA and regulatory status
- EFSA: No approved health claims for NMN. The EFSA register has no entries permitting lifespan, longevity, or “anti-ageing gene activation” claims.
- Regulatory context generally: Claims about lifespan extension or “longevity gene” activation are not legally usable for food supplements in the EU under Regulation (EC) No 1924/2006.
Verdict
Exaggerated. The underlying research area — NAD+ metabolism, sirtuins, and ageing biology — is a legitimate and active field of science. The direct claim that NMN extends human lifespan is not supported by human data and is not legally permissible as advertising language in the EU. The honest framing of NMN is as a compound with interesting preclinical signals and limited, early-stage human evidence — not as a proven longevity drug.